{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:53:00Z","timestamp":1789678380468,"version":"4.0.1"},"reference-count":326,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pharmthera.2019.107417","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T11:33:39Z","timestamp":1571225619000},"page":"107417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential"],"prefix":"10.1016","volume":"205","author":[{"given":"Guy A.","family":"Higgins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Shanahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2019.107417_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.regpep.2007.10.006","article-title":"Brain circuits regulating energy homeostasis","volume":"149","author":"Abizaid","year":"2009","journal-title":"Regulatory Peptides"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0010","series-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/npp.2013.199","article-title":"Functional status of the serotonin 5-HT2C receptor (5-HT2CR) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence","volume":"39","author":"Anastasio","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2019.107417_bib0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acschemneuro.5b00094","article-title":"Serotonin (5-HT) 5-HT2A receptor (5-HT2AR):5-HT2CR imbalance in medial prefrontal cortex associates with motor impulsivity","volume":"6","author":"Anastasio","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0025","series-title":"FDA briefing document. Lorcaserin hydrochloride. NDA 22-529. 13th August 2010","author":"Arena Pharmaceuticals","year":"2010"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0030","series-title":"FDA briefing document. Lorcaserin hydrochloride. NDA 22-529. 6th April 2012","author":"Arena Pharmaceuticals","year":"2012"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.10.2817","article-title":"Safety and efficacy of lorcaserin: A combined analysis of the BLOOM and BLOSSOM trials","volume":"126","author":"Aronne","year":"2014","journal-title":"Postgraduate Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005347","article-title":"Independent neuronal origin of seizures and behavioral comorbidities in an animal model of a severe childhood genetic epileptic encephalopathy","volume":"11","author":"Asinof","year":"2015","journal-title":"PLoS Genetics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0045","doi-asserted-by":"crossref","first-page":"e4439","DOI":"10.1136\/bmj.e4439","article-title":"Weight gain in smokers after quitting cigarettes: Meta-analysis","volume":"345","author":"Aubin","year":"2012","journal-title":"BMJ."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0050","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.appet.2010.09.010","article-title":"The study of food addiction using animal models of binge eating","volume":"55","author":"Avena","year":"2010","journal-title":"Appetite"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib0055","first-page":"77S","article-title":"Agonist-directed signaling of serotonin 5-HT2C receptors: Differences between serotonin and lysergic acid diethylamide (LSD)","volume":"21","author":"Backstrom","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0060","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/npp.2016.259","article-title":"Repeated 7-Day treatment with the 5-HT2C agonist lorcaserin or the 5-HT2A antagonist pimavanserin alone or in combination fails to reduce cocaine vs food choice in male Rhesus monkeys","volume":"42","author":"Banks","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0065","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nprot.2008.41","article-title":"The application of the 5-choice serial reaction time task for the assessment of visual attentional processes and impulse control in rats","volume":"3","author":"Bari","year":"2008","journal-title":"Nature Protocols"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0070","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.neuroimage.2010.05.059","article-title":"Body mass correlates inversely with inhibitory control in response to food among adolescent girls: An fMRI study","volume":"52","author":"Batterink","year":"2010","journal-title":"Neuroimage."},{"issue":"5881","key":"10.1016\/j.pharmthera.2019.107417_bib0075","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1126\/science.1158136","article-title":"High impulsivity predicts the switch to compulsive cocaine-taking","volume":"320","author":"Belin","year":"2008","journal-title":"Science."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1476-5381.1990.tb14138.x","article-title":"Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice","volume":"101","author":"Berendsen","year":"1990","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02253718","article-title":"Involvement of 5-HT1C-receptors in drug-induced penile erections in rats","volume":"101","author":"Berendsen","year":"1990","journal-title":"Psychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0026-895X(25)09724-X","article-title":"Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems","volume":"46","author":"Berg","year":"1994","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/mol.54.1.94","article-title":"Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus","volume":"54","author":"Berg","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0100","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.bjp.0704255","article-title":"RNA-editing of the 5-HT2C receptor alters agonist-receptor-effector coupling specificity","volume":"134","author":"Berg","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0105","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.131524","article-title":"A conservative, single-amino acid substitution in the second cytoplasmic domain of the human serotonin 2C receptor alters both ligand-dependent and \u2013independent receptor signaling","volume":"324","author":"Berg","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.11.002","article-title":"Parallel, redundant circuit organization for homeostatic control of feeding behavior","volume":"155","author":"Betley","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neulet.2018.09.028","article-title":"d-Fenfluramine and lorcaserin inhibit the binge-like feeding induced by \u03bc-opioid receptor stimulation of the nucleus accumbens in the rat","volume":"687","author":"Blumenthal","year":"2018","journal-title":"Neuroscience Letters"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0195-6663(86)80051-4","article-title":"Serotonin manipulations and the structure of feeding behaviour","volume":"7","author":"Blundell","year":"1986","journal-title":"Appetite"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0125","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000368783","article-title":"Beyond BMI--phenotyping the obesities","volume":"7","author":"Blundell","year":"2014","journal-title":"Obesity Facts"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2018.03.012","article-title":"Design and rationale for the cardiovascular and metabolic effects of Lorcaserin in overweight and obese patients-thrombolysis in myocardial infarction 61 (CAMELLIA-TIMI 61) trial","volume":"202","author":"Bohula","year":"2018","journal-title":"American Heart Journal"},{"issue":"10161","key":"10.1016\/j.pharmthera.2019.107417_bib0135","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/S0140-6736(18)32328-6","article-title":"Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomised, placebo-controlled trial","volume":"392","author":"Bohula","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107417_bib0140","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","article-title":"Cardiovascular safety of Lorcaserin in overweight or obese patients","volume":"379","author":"Bohula","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2019.107417_bib0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-013-3120-y","article-title":"The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research","volume":"229","author":"Bossert","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12328","article-title":"Update on obesity pharmacotherapy","volume":"1311","author":"Bray","year":"2014","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0897-387","article-title":"Sound-induced seizures in serotonin 5-HT2C receptor mutant mice","volume":"16","author":"Brennan","year":"1997","journal-title":"Nature Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14728214.2018.1552937","article-title":"Emerging drugs for the treatment of Dravet syndrome","volume":"23","author":"Brigo","year":"2018","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.12.004","article-title":"Dextromethorphan interactions with histaminergic and serotonergic treatments to reduce nicotine self-administration in rats","volume":"142","author":"Briggs","year":"2016","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib0175","first-page":"31","article-title":"CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence","volume":"51","author":"Brown","year":"1990","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020508","article-title":"5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway","volume":"6","author":"Bubar","year":"2011","journal-title":"PloS One"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib0185","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1210\/en.2014-1223","article-title":"5-HT obesity medication efficacy via POMC activation is maintained during aging","volume":"155","author":"Burke","year":"2014","journal-title":"Endocrinology."},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib0190","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.molmet.2017.07.004","article-title":"Lorcaserin improves glycemic control via a melanocortin neurocircuit","volume":"6","author":"Burke","year":"2017","journal-title":"Molecular Metabolism"},{"issue":"6630","key":"10.1016\/j.pharmthera.2019.107417_bib0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/387303a0","article-title":"Regulation of serotonin-2C receptor G-protein coupling by RNA editing","volume":"387","author":"Burns","year":"1997","journal-title":"Nature."},{"issue":"1-2","key":"10.1016\/j.pharmthera.2019.107417_bib0200","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(94)90690-4","article-title":"Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP)","volume":"257","author":"Callahan","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.neuropharm.2013.04.030","article-title":"The use of the reinstatement model to study relapse to palatable food seeking during dieting","volume":"76","author":"Calu","year":"2014","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology."},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0215","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.113.212373","article-title":"A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist\/5-HT2B inverse agonist with preclinical efficacy for psychoses","volume":"349","author":"Canal","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0220","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1358\/mf.2000.22.5.796647","article-title":"Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: A meta-analysis","volume":"22","author":"Carvajal","year":"2000","journal-title":"Methods and Findings in Experimental and Clinical Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vascn.2013.12.004","article-title":"Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy","volume":"69","author":"Cavero","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0230","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia."},{"issue":"15","key":"10.1016\/j.pharmthera.2019.107417_bib0235","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1080\/14656566.2016.1234609","article-title":"Pimavanserin for the treatment of Parkinson\u2019s disease psychosis","volume":"17","author":"Chendo","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0240","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/jm5019274","article-title":"Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents","volume":"58","author":"Cheng","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"21","key":"10.1016\/j.pharmthera.2019.107417_bib0245","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1021\/acs.jmedchem.6b01194","article-title":"Design and discovery of functionally selective serotonin 2C (5-HT2C) receptor agonists","volume":"59","author":"Cheng","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0250","first-page":"73","article-title":"Cue reactivity and cue reactivity interventions in drug dependence","volume":"137","author":"Childress","year":"1993","journal-title":"NIDA Research Monograph"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib0255","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.clinthera.2016.08.016","article-title":"Single- and multiple-dose pharmacokinetics of a lorcaserin extended-release tablet","volume":"38","author":"Christopher","year":"2016","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0260","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.clinthera.2017.03.004","article-title":"Pharmacokinetics and tolerability of lorcaserin in special populations: Elderly patients and patients with renal or hepatic impairment","volume":"39","author":"Christopher","year":"2017","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0265","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s002130000504","article-title":"Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat","volume":"152","author":"Clifton","year":"2000","journal-title":"Psychopharmacology (Berlin)"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0270","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1037\/pha0000209","article-title":"Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys","volume":"26","author":"Collins","year":"2018","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2017.12.023","article-title":"The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders","volume":"142","author":"Collins","year":"2018","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/jpet.115.228833","article-title":"Lorcaserin reduces the discriminative stimulus and reinforcing effects of cocaine in Rhesus monkeys","volume":"356","author":"Collins","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0285","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","article-title":"The FDA\u2019s assessment of two drugs for chronic weight management","volume":"367","author":"Colman","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0290","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nn1455","article-title":"Anatomy and regulation of the central melanocortin system","volume":"8","author":"Cone","year":"2005","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0295","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.physbeh.2011.04.041","article-title":"Feeding and reward: Perspectives from three rat models of binge eating","volume":"104","author":"Corwin","year":"2011","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0305","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2014.06.004","article-title":"IV nicotine self-administration in rats using a consummatory operant licking response: Sensitivity to serotonergic, glutaminergic and histaminergic drugs","volume":"54","author":"Cousins","year":"2014","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0310","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40608-016-0122-4","article-title":"A randomized, open-label pilot of the combination of low-level laser therapy and lorcaserin for weight loss","volume":"3","author":"Croghan","year":"2016","journal-title":"BMC Obesity"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib0315","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-3565(24)39013-5","article-title":"Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors","volume":"295","author":"Cryan","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/cn300072u","article-title":"Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction","volume":"4","author":"Cunningham","year":"2013","journal-title":"ACS Chemical Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0325","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cmet.2018.07.017","article-title":"Nucleus of the solitary tract serotonin 5-HT2C receptors modulate food intake","volume":"28","author":"D\u2019Agostino","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0330","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.neuron.2011.01.020","article-title":"Impulsivity, compulsivity, and top-down cognitive control","volume":"69","author":"Dalley","year":"2011","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0335","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.neuropharm.2003.11.012","article-title":"mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes","volume":"46","author":"Dalton","year":"2004","journal-title":"Neuropharmacology."},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cbdd.12045","article-title":"Putative impact of RNA editing on drug discovery","volume":"81","author":"Decher","year":"2013","journal-title":"Chemical Biology & Drug Design"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0345","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0028-3908(98)00203-2","article-title":"Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: A pharmacological analysis","volume":"38","author":"Dekeyne","year":"1999","journal-title":"Neuropharmacology."},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0350","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study","volume":"3","author":"Diabetes Prevention Program Research Group","year":"2015","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0355","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1037\/a0016504","article-title":"Trait impulsivity predicts escalation of sucrose seeking and hypersensitivity to sucrose-associated stimuli","volume":"123","author":"Diergaarde","year":"2009","journal-title":"Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0360","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2007.07.011","article-title":"Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats","volume":"63","author":"Diergaarde","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0365","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0091-3057(01)00705-5","article-title":"Role of serotonin(2C) receptors in the control of brain dopaminergic function","volume":"71","author":"DiMatteo","year":"2002","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0006-8993(00)02246-0","article-title":"Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors","volume":"865","author":"Di Matteo","year":"2000","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0375","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pbb.2018.11.002","article-title":"Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin","volume":"176","author":"DiPalma","year":"2019","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"17","key":"10.1016\/j.pharmthera.2019.107417_bib0380","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/eurheartj\/ehm263","article-title":"In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology","volume":"28","author":"Droogmans","year":"2007","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib0385","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.111.179572","article-title":"Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist","volume":"337","author":"Dunlop","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: An update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0395","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/PL00005481","article-title":"Varieties of impulsivity","volume":"146","author":"Evenden","year":"1999","journal-title":"Psychopharmacology (Berlin)"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0400","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nn1579","article-title":"Neural systems of reinforcement for drug addiction: From actions to habits to compulsion","volume":"8","author":"Everitt","year":"2005","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0405","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-psych-122414-033457","article-title":"Drug addiction: Updating actions to habits to compulsions ten years on","volume":"67","author":"Everitt","year":"2016","journal-title":"Annual Review of Psychology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0410","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-methoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","author":"Fantegrossi","year":"2010","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0415","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2337\/db16-0635","article-title":"Lorcaserin administration decreases activation of brain centers in response to food cues and these emotion- and salience-related changes correlate with weight loss effects: A 4-Week-Long randomized, placebo-controlled, double-blind clinical trial","volume":"65","author":"Farr","year":"2016","journal-title":"Diabetes."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0420","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbr.2018.03.006","article-title":"5-HT2C receptors in the ventral tegmental area, but not in the arcuate nucleus, mediate the hypophagic and hypolocomotor effects of the selective 5-HT2C receptor agonist AR231630 in rats","volume":"347","author":"Faton","year":"2018","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0425","series-title":"Lorcaserin hydrochloride. NDA 22-529. Endocrinologic and Metabolic Drugs Advisory Committee Meeting \u2013 May 10th, 2012","author":"FDA Briefing Doc","year":"2012"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0430","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2019.01.037","article-title":"Ligand-directed serotonin 5-HT2C receptor desensitization and sensitization","volume":"848","author":"Felsing","year":"2019","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0435","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0440","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1001\/jama.2013.281501","article-title":"The merits of subtyping obesity: One size does not fit all","volume":"310","author":"Field","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0445","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.neuroimage.2012.08.073","article-title":"Reward circuit function in high BMI individuals with compulsive overeating: Similarities with addiction","volume":"63","author":"Filbey","year":"2012","journal-title":"Neuroimage."},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0450","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0455","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF02246545","article-title":"5-HT2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine","volume":"122","author":"Fiorella","year":"1995","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Molecular Pharmacology"},{"issue":"2 Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib0465","doi-asserted-by":"crossref","first-page":"82S","DOI":"10.1038\/sj.npp.1395328","article-title":"Messenger RNA editing of the human serotonin 5-HT2C receptor","volume":"21","author":"Fitzgerald","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0470","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/adb.12602","article-title":"Preclinical evidence for combining the 5-HT2C receptor agonist lorcaserin and varenicline as a treatment for nicotine dependence","volume":"24","author":"Fletcher","year":"2019","journal-title":"Addiction Biology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0475","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.neuropharm.2009.05.011","article-title":"Characterizing the effects of 5-HT2C receptor ligands on motor activity and feeding behaviour in 5-HT2C receptor knockout mice","volume":"57","author":"Fletcher","year":"2009","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0480","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.neuropharm.2011.02.025","article-title":"Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade","volume":"61","author":"Fletcher","year":"2011","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0485","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pbb.2010.07.002","article-title":"Genetic and pharmacological evidence that 5-HT2C receptor activation, but not inhibition, affects motivation to feed under a progressive ratio schedule of reinforcement","volume":"97","author":"Fletcher","year":"2010","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0490","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/osp4.335","article-title":"Effect of lorcaserin in different age groups: A post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies","volume":"5","author":"Fujioka","year":"2019","journal-title":"Obesity Science & Practice"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0495","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/osp4.340","article-title":"Effect of lorcaserin on weight reduction in persons with obstructive sleep apnea (OSA): A combined subgroup analysis from three randomized, controlled clinical trials","volume":"5","author":"Fujioka","year":"2019","journal-title":"Obesity Science & Practice"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib0500","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S2213-8587(17)30312-1","article-title":"Precision medicine: Diagnosis and management of obesity","volume":"6","author":"Fr\u00fchbeck","year":"2018","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.yfrne.2009.10.003","article-title":"Appetite and reward","volume":"31","author":"Fulton","year":"2010","journal-title":"Frontiers in Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0510","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","article-title":"Identification of new epilepsy treatments: Issues in preclinical methodology","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0515","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nbd.2015.04.015","article-title":"Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical + studies","volume":"79","author":"Galanopoulou","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0520","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.246082","article-title":"Inhibition of cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) self-administration by lorcaserin is mediated by 5-HT2C receptors in rats","volume":"364","author":"Gannon","year":"2018","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib0525","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0195-6663(86)80050-2","article-title":"Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system","volume":"7","author":"Garattini","year":"1986","journal-title":"Appetite"},{"issue":"13","key":"10.1016\/j.pharmthera.2019.107417_bib0530","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0535","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archgenpsychiatry.2011.32","article-title":"Neural correlates of food addiction","volume":"68","author":"Gearhardt","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0540","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1176\/ajp.154.1.81","article-title":"Behavioral and neuroendocrine responses to m-chlorophenylpiperazine in subtypes of alcoholics and in healthy comparison subjects","volume":"154","author":"George","year":"1997","journal-title":"The American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0545","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1037\/pha0000234","article-title":"Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys","volume":"27","author":"Gerak","year":"2019","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0550","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.116.236307","article-title":"Effects of lorcaserin on cocaine and methamphetamine self-administration and reinstatement of responding previously maintained by cocaine in Rhesus monkeys","volume":"359","author":"Gerak","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2019.107417_bib0555","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: Contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0560","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1098-2396(20000601)36:3<205::AID-SYN5>3.0.CO;2-D","article-title":"Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat","volume":"36","author":"Gobert","year":"2000","journal-title":"Synapse."},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib0565","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/00008877-200112000-00005","article-title":"m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors","volume":"12","author":"Gleason","year":"2001","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0570","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.addbeh.2014.04.022","article-title":"Impulsive action and impulsive choice across substance and behavioral addictions: cause or consequence?","volume":"39","author":"Grant","year":"2014","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0575","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cob.12159","article-title":"Safety and tolerability review of lorcaserin in clinical trials","volume":"6","author":"Greenway","year":"2016","journal-title":"Clinical Obesity"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0580","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fphar.2018.00573","article-title":"Preclinical animal models for dravet syndrome: Seizure phenotypes, comorbidities d drug + screening","volume":"9","author":"Griffin","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0585","first-page":"669","article-title":"Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome","volume":"140","author":"Griffin","year":"2017","journal-title":"Brain."},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib0590","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","article-title":"Target site occupancy: Emerging generalizations from clinical and preclinical studies","volume":"122","author":"Grimwood","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0595","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00213-014-3829-2","article-title":"Investigating interactions between phentermine, dexfenfluramine, and 5-HT2C agonists, on food intake in the rat","volume":"232","author":"Grottick","year":"2015","journal-title":"Psychopharmacology (Berlin)"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0600","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2009.10.007","article-title":"Placebo responses in randomized trials of antiepileptic drugs","volume":"17","author":"Guekht","year":"2010","journal-title":"Epilepsy & Behavior"},{"issue":"9","key":"10.1016\/j.pharmthera.2019.107417_bib0605","first-page":"525","article-title":"Lorcaserin (Belviq): A selective serotonin 5-HT2C agonist in the treatment of obesity","volume":"38","author":"Gustafson","year":"2013","journal-title":"Pharmacy and Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107417_bib0610","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.0000159356.42064.48","article-title":"Long-term serotonin administration induces heart valve disease in rats","volume":"111","author":"Gustafsson","year":"2005","journal-title":"Circulation."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0615","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/FBP.0000000000000092","article-title":"Examination of the effects of varenicline, bupropion, lorcaserin, or naltrexone on responding for conditioned reinforcement in nicotine-exposed rats","volume":"25","author":"Guy","year":"2015","journal-title":"Behavioural Pharmacology"},{"issue":"8672","key":"10.1016\/j.pharmthera.2019.107417_bib0620","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(89)91499-2","article-title":"International trial of long-term dexfenfluramine in obesity","volume":"2","author":"Guy-Grand","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0625","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbr.2013.08.045","article-title":"Animal models of the serotonin syndrome: A systematic review","volume":"256","author":"Haberzettl","year":"2013","journal-title":"Behav Brain Res."},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib0630","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology."},{"issue":"17","key":"10.1016\/j.pharmthera.2019.107417_bib0635","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.2165\/11596680-000000000-00000","article-title":"Serotonergic anti-obesity agents: Past experience and future prospects","volume":"71","author":"Halford","year":"2011","journal-title":"Drugs."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0640","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-181121","article-title":"The alzheimer precision medicine initiative","author":"Hampel","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0645","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrendo.2012.175","article-title":"Obesity: is weight gain after smoking cessation an important concern?","volume":"8","author":"Hankey","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0650","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbr.2008.03.020","article-title":"Molecular biology of 5-HT receptors","volume":"195","author":"Hannon","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0655","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2015.09.028","article-title":"The 5-HT(2C) receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity","volume":"101","author":"Harvey-Lewis","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0660","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neuropharm.2012.01.017","article-title":"What is the prognosis for new centrally-acting anti-obesity drugs?","volume":"63","author":"Heal","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0665","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1126\/science.1072327","article-title":"Activation of central melanocortin pathways by fenfluramine","volume":"297","author":"Heisler","year":"2002","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0670","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1046\/j.1471-4159.1999.731711.x","article-title":"Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: Implications for serotonergic signal transduction","volume":"73","author":"Herrick-Davis","year":"1999","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0675","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0091-3057(01)00709-2","article-title":"Serotonin 2C receptor agonists and the behavioural satiety sequence in mice","volume":"71","author":"Hewitt","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0680","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/acschemneuro.7b00133","article-title":"18F-FPP: A PET ligand for the 5-HT2C receptor?","volume":"8","author":"Higgins","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0685","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.84","article-title":"Characterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity","volume":"3","author":"Higgins","year":"2014","journal-title":"Pharmacology Research & Perspectives"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0690","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejphar.2003.08.102","article-title":"Serotonin and reward: Focus on 5-HT2C receptors","volume":"480","author":"Higgins","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0695","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1021\/acschemneuro.5b00025","article-title":"Therapeutic potential of 5-HT2C receptor agonists for addictive disorders","volume":"6","author":"Higgins","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0700","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.bjp.0704082","article-title":"Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine","volume":"133","author":"Higgins","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0705","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tips.2013.08.001","article-title":"From obesity to substance abuse: Therapeutic opportunities for 5-HT2C receptor agonists","volume":"34","author":"Higgins","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0710","article-title":"Rodent test of attention and impulsivity: The 5-Choice serial reaction time task","volume":"78","author":"Higgins","year":"2017","journal-title":"Current Protocols in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0715","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s00213-016-4329-3","article-title":"Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists","volume":"233","author":"Higgins","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0720","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00213-012-2919-2","article-title":"Evaluation of chemically diverse 5-HT2C receptor agonists on behaviours motivated by food and nicotine and on side effect profiles","volume":"226","author":"Higgins","year":"2013","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0725","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1021\/acschemneuro.6b00444","article-title":"Studies to examine potential tolerability differences between the 5-HT2C receptor selective agonists lorcaserin and CP-809101","volume":"8","author":"Higgins","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0730","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/npp.2011.303","article-title":"The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination and reinstatement: Relationship to feeding behavior and impulse control","volume":"37","author":"Higgins","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0735","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0269881117735797","article-title":"Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists","volume":"31","author":"Higgins","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0740","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-015-4112-x","article-title":"The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour","volume":"233","author":"Higgs","year":"2016","journal-title":"Psychopharmacology (Berlin)"},{"issue":"3483","key":"10.1016\/j.pharmthera.2019.107417_bib0745","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0750","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ADM.0b013e31819aa621","article-title":"Natural addiction: A behavioural circuit model based on sugar addiction in rats","volume":"3","author":"Hoebel","year":"2009","journal-title":"Journal of Addiction Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib0755","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1523\/JNEUROSCI.17-08-02796.1997","article-title":"Effects of m-chlorophenylpiperazine on regional brain glucose utilization: A positron emission tomographic comparison of alcoholic and control subjects","volume":"17","author":"Hommer","year":"1997","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0760","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/pr.114.009514","article-title":"Serotonin 5-HT2 receptor interactions with dopamine function: Implications for therapeutics in cocaine use disorder","volume":"67","author":"Howell","year":"2015","journal-title":"Pharmacological Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0765","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040889","article-title":"Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT2c) Receptor Agonists in the Ventral Tegmental Area (VTA) Inhibit Ghrelin-Stimulated Appetitive Reward","volume":"20","author":"Howell","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0770","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacological Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib0775","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Movement Disorders"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib0780","first-page":"994","article-title":"Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: A pilot study","volume":"19","author":"Hurt","year":"2017","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0785","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/DMSO.S126855","article-title":"Challenging obesity, diabetes, and addiction: The potential of lorcaserin extended release","volume":"11","author":"Hurt","year":"2018","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0790","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease - it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0795","series-title":"Poster Presented at Obesity Week; T-2580-P","article-title":"Characterization of hypoglycemia in patients with type 2 diabetes with lorcaserin therapy during the BLOOM-DM phase III study","author":"Inzucchi","year":"2014"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0800","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568026053386980","article-title":"Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs","volume":"5","author":"Isaac","year":"2005","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib0805","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0024-3205(76)90303-9","article-title":"An animal behavior model for studying central serotonergic synapses","volume":"19","author":"Jacobs","year":"1976","journal-title":"Life Science"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0810","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2017.09.008","article-title":"Effects of lorcaserin (Belviq\u00ae) on nicotine- and food-maintained responding in non-human primates","volume":"181","author":"Jacobs","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0815","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.108.180976","article-title":"Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy","volume":"104","author":"Jaffr\u00e9","year":"2008","journal-title":"Circulation Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0820","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)00775-0","article-title":"Pharmacological characterisation of human 5-HT2 receptor subtypes","volume":"414","author":"Jerman","year":"2001","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0825","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0006-3223(90)90412-U","volume":"28","author":"Jimerson","year":"1990","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib0830","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nn.2519","article-title":"Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats","volume":"13","author":"Johnson","year":"2010","journal-title":"Nature Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0835","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","article-title":"GABAA receptor occupancy by subtype selective GABAA\u03b12,3 modulators: PET studies in humans","volume":"234","author":"Jucaite","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0840","first-page":"302","article-title":"Highly impulsive rats: Modelling an endophenotype to determine the neurobiological, genetic and environmental mechanisms of addiction","volume":"6","author":"Jupp","year":"2013","journal-title":"Disease Models & Mechanisms"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0845","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1210\/jc.2004-0165","article-title":"Metabolic and body composition factors in subgroups of obesity: What do we know?","volume":"89","author":"Karelis","year":"2004","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib0850","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-3565(25)12956-X","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0855","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0031-9384(02)00751-5","article-title":"Opioid modulation of taste hedonics within the ventral striatum","volume":"76","author":"Kelley","year":"2002","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0860","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pbb.2010.07.020","article-title":"New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?","volume":"97","author":"Kennett","year":"2010","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0865","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1988.tb11508.x","article-title":"Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors","volume":"94","author":"Kennett","year":"1988","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0870","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB242,084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0875","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.neuron.2011.02.016","article-title":"Reward mechanisms in obesity: New insights and future directions","volume":"69","author":"Kenny","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0880","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.biopsych.2012.11.020","article-title":"The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys","volume":"73","author":"Kessler","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib0885","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs","volume":"339","author":"Khan","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.pharmthera.2019.107417_bib0890","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA."},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib0895","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0304-3959(92)90041-9","article-title":"An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat","volume":"50","author":"Kim","year":"1992","journal-title":"Pain."},{"issue":"3-4","key":"10.1016\/j.pharmthera.2019.107417_bib0900","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02245211","article-title":"An examination of the behavioural specificity of hypophagia induced by 5-HT1B, 5-HT1C and 5-HT2 receptor agonists using the post-prandial satiety sequence in rats","volume":"113","author":"Kitchener","year":"1994","journal-title":"Psychopharmacology (Berlin)"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib0905","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0910","article-title":"Pretreatment with either a 5-HT2C agonist or 5-HT2A antagonist decreases cocaine self-administration","volume":"28","author":"Kohut","year":"2014","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0915","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2018.09.025","article-title":"Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys","volume":"840","author":"Kohut","year":"2018","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0920","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/epi.14540","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"59","author":"Lagae","year":"2018","journal-title":"Epilepsia."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0925","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1517\/13543776.2010.518956","article-title":"5-HT2C receptor modulators: A patent survey","volume":"20","author":"Lee","year":"2010","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0930","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1124\/jpet.111.183525","article-title":"Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats","volume":"338","author":"Levin","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"9626","key":"10.1016\/j.pharmthera.2019.107417_bib0935","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","article-title":"The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study","volume":"371","author":"Li","year":"2008","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib0940","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: A 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"368","key":"10.1016\/j.pharmthera.2019.107417_bib0945","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study","volume":"2006","author":"Lindstrom","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib0950","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.neuroscience.2007.02.064","article-title":"Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: Implications for understanding the neurobiology of addiction","volume":"146","author":"Liu","year":"2007","journal-title":"Neuroscience."},{"key":"10.1016\/j.pharmthera.2019.107417_bib0955","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1124\/dmd.105.008201","article-title":"Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration","volume":"34","author":"Liu","year":"2006","journal-title":"Drug Metabolism and Disposition"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0960","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","author":"Lunn","year":"2014","journal-title":"Cochrane Database System Review"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2019.107417_bib0965","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1242\/jcs.115.3.455","article-title":"The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals","volume":"115","author":"Luttrell","year":"2002","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0970","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2015.01.009","article-title":"Structure and function of serotonin G protein-coupled receptors","volume":"150","author":"McCorvy","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib0975","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0197-0186(02)00093-1","article-title":"[3H]-ketanserin binding sites in different psychiatric disorders","volume":"42","author":"Marazziti","year":"2003","journal-title":"Neurochemistry International"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib0980","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0924-977X(99)00045-0","article-title":"Distribution and characterization of [3H]mesulergine binding in human brain postmortem","volume":"10","author":"Marazziti","year":"1999","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0985","first-page":"12","article-title":"Specific treatment of residual fatigue in depressed patients","volume":"1","author":"Marin","year":"2004","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0990","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jc.2010-1848","article-title":"Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure","volume":"96","author":"Martin","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2019.107417_bib0995","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3565(24)37669-4","article-title":"5-HT2C receptor agonists: Pharmacological characteristics and therapeutic potential","volume":"286","author":"Martin","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib1000","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0091-3057(01)00713-4","article-title":"Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety","volume":"71","author":"Martin","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-0037-1601324","article-title":"Lennox-gastaut syndrome: A state of the art review","volume":"48","author":"Mastrangelo","year":"2017","journal-title":"Neuropediatrics."},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib1010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0893-133X(95)00274-H","article-title":"Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures","volume":"14","author":"Mello","year":"1996","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/PGPM.S146110","article-title":"Precision pharmacotherapy: Psychiatry\u2019s future direction in preventing, diagnosing, and treating mental disorders","volume":"11","author":"Menke","year":"2018","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1020","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pec.2010.03.003","article-title":"Obesity and the four facets of impulsivity","volume":"79","author":"Mobbs","year":"2010","journal-title":"Patient Education and Counseling"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0079-6468(07)00006-9","article-title":"5-HT2C ligands: Recent progress","volume":"46","author":"Monck","year":"2008","journal-title":"Progress in Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib1030","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1017\/S0033291798006904","article-title":"Plasma prolactin response to D-fenfluramine is blunted in bulimic patients with frequent binge episodes","volume":"28","author":"Monteleone","year":"1998","journal-title":"Psychological Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib1035","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1017\/S0033291799002330","article-title":"Serotonergic dysfunction across the eating disorders: Relationship to eating behaviour, purging behaviour, nutritional status and general psychopathology","volume":"30","author":"Monteleone","year":"2000","journal-title":"Psychological Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.neuropharm.2013.04.051","article-title":"Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: Potential utility as antipsychotic medications","volume":"72","author":"Morgan","year":"2013","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nature05026","article-title":"Central nervous system control of food intake and body weight","volume":"443","author":"Morton","year":"2006","journal-title":"Nature."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1050","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/jpet.106.117507","article-title":"Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors","volume":"321","author":"Moya","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2019.107417_bib1055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2009.05.024","article-title":"Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia","volume":"146","author":"Nagakura","year":"2009","journal-title":"Pain."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pneurobio.2009.05.003","article-title":"The neuropharmacology of relapse to food seeking: Methodology, main findings, and comparison with relapse to drug seeking","volume":"89","author":"Nair","year":"2009","journal-title":"Progress in Neurobiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib1065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ejpain.2010.04.008","article-title":"5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain","volume":"14","author":"Nakai","year":"2010","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.npp.1301414","article-title":"Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine","volume":"33","author":"Navailles","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1075","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib1080","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.clinthera.2016.04.004","article-title":"Lorcaserin in obese and overweight patients taking prohibited serotonergic agents: A retrospective analysis","volume":"38","author":"Nguyen","year":"2014","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib1085","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1090","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4088\/JCP.v60n0403","article-title":"Residual symptoms in depressed patients who respond acutely to fluoxetine","volume":"60","author":"Nierenberg","year":"1999","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1095","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1021\/jm058240i","article-title":"5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential anti-obesity agents","volume":"49","author":"Nilsson","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.pharmthera.2019.107417_bib1100","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1074\/jbc.274.14.9472","article-title":"RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity","volume":"274","author":"Niswender","year":"1999","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neuroscience.2015.03.050","article-title":"Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex","volume":"297","author":"Nocjar","year":"2015","journal-title":"Neuroscience."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0269881106069938","article-title":"The other face of depression, reduced positive affect: The role of catecholamines in causation and cure","volume":"21","author":"Nutt","year":"2007","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib1115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.nbd.2011.08.026","article-title":"Quantitative analysis of 5HT(2C) receptor RNA editing patterns in psychiatric disorders","volume":"45","author":"O\u2019Neil","year":"2012","journal-title":"Neurobiology of Disease"},{"issue":"7","key":"10.1016\/j.pharmthera.2019.107417_bib1120","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study","volume":"20","author":"O\u2019Neil","year":"2012","journal-title":"Obesity (Silver Spring)."},{"issue":"1-2","key":"10.1016\/j.pharmthera.2019.107417_bib1125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2007.03.029","article-title":"Possible involvement of spinal noradrenergic mechanisms in the antiallodynic effect of intrathecally administered 5-HT2C receptor agonists in the rats with peripheral nerve injury","volume":"567","author":"Obata","year":"2007","journal-title":"European Journal of Pharmacology"},{"issue":"1-2","key":"10.1016\/j.pharmthera.2019.107417_bib1130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pain.2003.12.019","article-title":"Antiallodynic effects of intrathecally administered 5-HT(2C) receptor agonists in rats with nerve injury","volume":"108","author":"Obata","year":"2004","journal-title":"Pain."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2013.04.007","article-title":"Systemic administration of 5-HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model","volume":"108","author":"Ogino","year":"2014","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"22","key":"10.1016\/j.pharmthera.2019.107417_bib1140","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s00213-017-4726-2","article-title":"Choice between delayed food and immediate opioids in rats: Treatment effects and individual differences","volume":"234","author":"Panlilio","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1145","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejphar.2013.09.070","article-title":"Conditioned flavor avoidance and conditioned gaping: Rat models of conditioned nausea","volume":"722","author":"Parker","year":"2014","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autneu.2006.07.022","article-title":"Conditioned gaping in rats: A selective measure of nausea","volume":"129","author":"Parker","year":"2006","journal-title":"Autonomic Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib1155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/med.20245","article-title":"5-HT radioligands for human brain imaging with PET and SPECT","volume":"33","author":"Paterson","year":"2013","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1160","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.conb.2013.01.023","article-title":"The role of impulsivity in relapse vulnerability","volume":"23","author":"Pattij","year":"2013","journal-title":"Current Opinion in Neurobiology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tips.2008.01.002","article-title":"The neuropharmacology of impulsive behaviour","volume":"29","author":"Pattij","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"issue":"9\u201310","key":"10.1016\/j.pharmthera.2019.107417_bib1170","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00213-017-4545-5","article-title":"A short history of the 5-HT2C receptor: From the choroid plexus to depression, obesity and addiction treatment","volume":"234","author":"Palacios","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib1175","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cell.2018.01.001","article-title":"5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology","volume":"172","author":"Peng","year":"2018","journal-title":"Cell."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1180","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/npp.2010.72","article-title":"Stimulation of medial prefrontal cortex serotonin 2C (5-HT2C) receptors attenuates cocaine-seeking behavior","volume":"35","author":"Pentkowski","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1185","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41386-018-0200-z","article-title":"Effects of long-term high-fat food or methamphetamine intake and serotonin 2C receptors on reversal learning in female rhesus macaques","volume":"44","author":"Perez Diaz","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-008-1173-0","article-title":"The role of impulsive behavior in drug abuse","volume":"200","author":"Perry","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1195","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pbb.2019.02.010","article-title":"The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study","volume":"180","author":"Pirtle","year":"2019","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107417_bib1200","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/syn.21592","article-title":"5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen","volume":"66","author":"Pockros","year":"2012","journal-title":"Synapse."},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib1205","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/npp.2017.52","article-title":"5-HT2C agonists modulate schizophrenia-like behaviors in mice","volume":"42","author":"Pogorelov","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0304-3940(90)90520-J","article-title":"Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-dophenyl aminopropane)-2 (DOI)","volume":"115","author":"Pranzatelli","year":"1990","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3389\/fphar.2018.00821","article-title":"Serotonin 5-HT2C receptor activation suppresses binge intake and the reinforcing and motivational properties of high-fat food","volume":"9","author":"Price","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1220","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fphar.2018.01424","article-title":"Pimavanserin and lorcaserin attenuate measures of binge eating in male sprague-dawley rats","volume":"9","author":"Price","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib1225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: An emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"Supplement 1","key":"10.1016\/j.pharmthera.2019.107417_bib1230","first-page":"A521","article-title":"Lorcaserin (lor) free plasma levels at recommended dose are sufficient to activate 5-HT2c but not 2a or 2b Receptors","volume":"63","author":"Ravussin","year":"2014","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmthera.2019.107417_bib1235","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s12325-016-0414-6","article-title":"Reward-induced eating: Therapeutic approaches to addressing food cravings","volume":"33","author":"Rebello","year":"2016","journal-title":"Advances in Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib1240","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/oby.22094","article-title":"Effect of Lorcaserin Alone and in combination with phentermine on food cravings after 12-Week treatment: A randomized substudy","volume":"26","author":"Rebello","year":"2018","journal-title":"Obesity (Silver Spring)."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1245","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pbb.2014.07.017","article-title":"Lorcaserin, a selective 5-HT2C receptor agonist, decreases alcohol intake in female alcohol preferring rats","volume":"125","author":"Rezvani","year":"2014","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1250","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00213-002-1154-7","article-title":"The 5-choice serial reaction time task: Behavioural pharmacology and functional neurochemistry","volume":"163","author":"Robbins","year":"2002","journal-title":"Psychopharmacology (Berlin)"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib1255","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00592-017-0994-x","article-title":"Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?","volume":"54","author":"Roberts","year":"2017","journal-title":"Acta Diabetology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pbb.2010.03.001","article-title":"Behavioural satiety sequence (BSS): Separating wheat from chaff in the behavioural pharmacology of appetite","volume":"97","author":"Rodgers","year":"2010","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fpsyt.2017.00089","article-title":"Behavioral effects of a novel benzofuranyl-piperazine Serotonin-2C receptor agonist suggest a potential therapeutic application in the treatment of obsessive-compulsive disorder","volume":"8","author":"Rodriguez","year":"2017","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1270","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pbb.2017.01.001","article-title":"Food and drug addictions: Similarities and differences","volume":"153","author":"Rogers","year":"2017","journal-title":"Pharmacology Biochemistry and Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1275","article-title":"Combination Lorcaserin and Nicotine Patch for Smoking Cessation Without Weight Gain","author":"Rose","year":"2019","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1280","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-642-25758-2_6","article-title":"5-HT(2C) agonists as therapeutics for the treatment of schizophrenia","volume":"213","author":"Rosenzweig-Lipson","year":"2012","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1285","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib1290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s002130100749","article-title":"Cross tolerance between anorectic action and induction of Fos-ir with dexfenfluramine and 5HT1B\/2C agonists in rats","volume":"156","author":"Rowland","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050407","article-title":"5-HT2C receptor activation decreases appetite and body weight in obese subjects","volume":"133","author":"Sargent","year":"1997","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1300","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/obr.12017","article-title":"Food-related impulsivity in obesity and binge eating disorder--a systematic review","volume":"14","author":"Schag","year":"2013","journal-title":"Obesity Reviews"},{"issue":"10","key":"10.1016\/j.pharmthera.2019.107417_bib1305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076542","article-title":"Impulsivity in binge eating disorder: Food cues elicit increased reward responses and disinhibition","volume":"8","author":"Schag","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1310","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.118.038341","article-title":"Lorcaserin and renal outcomes in obese and overweight patients in the CAMELLIA-TIMI 61 trial","volume":"139","author":"Scirica","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1315","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pharmthera.2008.11.005","article-title":"Physiological and pharmacological implications of beta-arrestin regulation","volume":"121","author":"Schmid","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1320","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/1756285615607726","article-title":"Low-dose fenfluramine in the treatment of neurologic disorders: Experience in Dravet syndrome","volume":"8","author":"Schoonjans","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1325","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.115.228148","article-title":"Directly observable behavioral effects of lorcaserin in rats","volume":"355","author":"Serafine","year":"2015","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2019.107417_bib1330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jeab.222","article-title":"Characterization of the discriminative stimulus effects of lorcaserin in rats","volume":"106","author":"Serafine","year":"2016","journal-title":"Journal of the Experimental Analysis of Behavior"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1224-x","article-title":"The reinstatement model of drug relapse: History, methodology and major findings","volume":"168","author":"Shaham","year":"2003","journal-title":"Psychopharmacology (Berlin)"},{"issue":"8","key":"10.1016\/j.pharmthera.2019.107417_bib1340","first-page":"944","article-title":"Lorcaserin for smoking cessation and associated weight gain: A randomized 12-Week clinical trial","volume":"19","author":"Shanahan","year":"2016","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1345","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"Journal of Psychiatric Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib1350","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2165\/00003495-198223060-00003","article-title":"Fixed combination drug therapy","volume":"23","author":"Shenfield","year":"1982","journal-title":"Drugs."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1355","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.2011.20","article-title":"Evaluation of the abuse potential evaluation of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users","volume":"89","author":"Shram","year":"2011","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1360","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1517\/14656566.2015.1096345","article-title":"Lorcaserin Hcl for the treatment of obesity","volume":"16","author":"Shukla","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1365","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acschemneuro.8b00739","article-title":"Evaluation of selective 5-HT2C agonists in acute seizure models","volume":"10","author":"Silenieks","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"issue":"Suppl","key":"10.1016\/j.pharmthera.2019.107417_bib1370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0195-6663(86)80054-X","article-title":"Serotoninergic mechanisms in human feeding: The pharmacological evidence","volume":"7","author":"Silverstone","year":"1986","journal-title":"Appetite"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199409000-00005","article-title":"The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers","volume":"9","author":"Silverstone","year":"1994","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1380","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuropharm.2006.07.024","article-title":"CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity","volume":"52","author":"Siuciak","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1385","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1111\/j.1460-9568.2007.05567.x","article-title":"5-HT2C receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice","volume":"25","author":"Somerville","year":"2007","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1390","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1021\/acschemneuro.5b00342","article-title":"Serotonergic modulation as effective treatment for dravet syndrome in a zebrafish mutant model","volume":"7","author":"Sourbron","year":"2016","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1395","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fphar.2017.00191","article-title":"Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish","volume":"8","author":"Sourbron","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1400","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm0709034","article-title":"Discovery and structure-activity relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity","volume":"51","author":"Smith","year":"2008","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib1405","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bmcl.2004.12.080","article-title":"Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity","volume":"15","author":"Smith","year":"2005","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1410","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.biopsych.2012.08.026","article-title":"The neurobiological underpinnings of obesity and binge eating: A rationale for adopting the food addiction model","volume":"73","author":"Smith","year":"2013","journal-title":"Biological Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib1415","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/oby.21811","article-title":"Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study","volume":"25","author":"Smith","year":"2017","journal-title":"Obesity (Silver Spring)."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1420","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/oby.20841","article-title":"Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes","volume":"22","author":"Smith","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1425","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","article-title":"Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women","volume":"17","author":"Smith","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1430","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicentre, placebo-controlled trial of lorcaserin for weight management","volume":"263","author":"Smith","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 14","key":"10.1016\/j.pharmthera.2019.107417_bib1435","first-page":"6","article-title":"Brain circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder","volume":"64","author":"Stahl","year":"2003","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1440","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1124\/jpet.302.3.957","article-title":"Rapid desensitization of the serotonin2C receptor system: Effector pathways and agonist dependence","volume":"302","author":"Stout","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1445","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.clinpsy.4.022007.141149","article-title":"Should binge eating disorder be included in the DSM-V? A critical review of the state of the evidence","volume":"4","author":"Striegel-Moore","year":"2008","journal-title":"Annual Review of Clinical Psychology"},{"issue":"6522","key":"10.1016\/j.pharmthera.2019.107417_bib1450","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib1455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00213-017-4764-9","article-title":"The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers","volume":"235","author":"Thomas","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1460","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3945\/ajcn.114.097543","article-title":"Satiation attenuates BOLD activity in brain regions involved in reward and increases activity in dorsolateral prefrontal cortex: An fMRI study in healthy volunteers","volume":"101","author":"Thomas","year":"2015","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1465","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"18","key":"10.1016\/j.pharmthera.2019.107417_bib1470","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.0000000000006432","article-title":"Lorcaserin therapy for severe epilepsy of childhood onset: A case series","volume":"91","author":"Tolete","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1475","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0014-2999(76)90266-1","article-title":"Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine","volume":"36","author":"Trulson","year":"1976","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1480","doi-asserted-by":"crossref","DOI":"10.1111\/dom.13655","article-title":"Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial","author":"Tuccinardi","year":"2019","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1485","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(18)32460-7","article-title":"Lorcaserin: Balancing efficacy with potential risks","volume":"392","author":"Unamuno","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmthera.2019.107417_bib1490","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1124\/jpet.113.207670","article-title":"Kinetics of 5-HT2B receptor signaling: Profound agonist-dependent effects on signaling onset and duration","volume":"347","author":"Unett","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nicl.2015.03.016","article-title":"Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity","volume":"8","author":"Val-Laillet","year":"2015","journal-title":"NeuroImage: Clinical"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1505","doi-asserted-by":"crossref","DOI":"10.1038\/npp.2016.264","article-title":"Activation of ventral tegmental area 5-HT2C receptors reduces incentive motivation","author":"Valencia-Torres","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1510","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/npp.2014.98","article-title":"High trait impulsivity predicts food addiction-like behavior in the rat","volume":"39","author":"Vel\u00e1zquez-S\u00e1nchez","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2016.04.016","article-title":"Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures","volume":"108","author":"Venzi","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.pharmthera.2019.107417_bib1520","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050952","article-title":"Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice","volume":"143","author":"Vickers","year":"1999","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1525","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0028-3908(01)00063-6","article-title":"Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors","volume":"41","author":"Vickers","year":"2001","journal-title":"Neuropharmacology"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2019.107417_bib1530","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0091-3057(01)00552-4","article-title":"Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists","volume":"69","author":"Vickers","year":"2001","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"5","key":"10.1016\/j.pharmthera.2019.107417_bib1535","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nn1452","article-title":"How can drug addiction help us understand obesity?","volume":"8","author":"Volkow","year":"2005","journal-title":"Nature Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2019.107417_bib1540","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn.2017.130","article-title":"The dopamine motive system: Implications for drug and food addiction","volume":"18","author":"Volkow","year":"2017","journal-title":"Nature Review Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1545","first-page":"438","article-title":"Agonists of the serotonin 5-HT2C receptor: Preclinical and clinical progression in multiple diseases","volume":"11","author":"Wacker","year":"2008","journal-title":"Current Opinion Drug Discovery Development"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1550","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/erv.952","article-title":"A systematic review of impulsivity in eating disorders","volume":"17","author":"Waxman","year":"2009","journal-title":"European Eating Disorders Review"},{"issue":"6","key":"10.1016\/j.pharmthera.2019.107417_bib1555","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1560","first-page":"560","article-title":"Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials","volume":"6","author":"Weissman","year":"2013","journal-title":"Circulation: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1565","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/oby.21695","article-title":"Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials","volume":"25","author":"Weissman","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1570","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/cn400186j","article-title":"Classics in chemical neuroscience: Fluoxetine (Prozac)","volume":"5","author":"Wenthur","year":"2014","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2019.107417_bib1575","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pharmthera.2008.03.012","article-title":"RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function","volume":"119","author":"Werry","year":"2008","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1580","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1021\/acs.jmedchem.8b00401","article-title":"Design, synthesis, and characterization of 4-Undecylpiperidine-2-carboxamides as positive allosteric modulators of the serotonin (5-HT) 5-HT2C receptor","volume":"62","author":"Wild","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2019.107417_bib1585","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1185\/030079907X182185","article-title":"A double-blind study evaluating the long-term safety of varenicline for smoking cessation","volume":"23","author":"Williams","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1590","doi-asserted-by":"crossref","DOI":"10.2174\/1568026619666190709101449","article-title":"Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development","author":"Wold","year":"2019","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2019.107417_bib1595","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"Case history: The discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"Wong","year":"2005","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1600","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2015.09.013","article-title":"Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice","volume":"607","author":"Wu","year":"2015","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1605","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2016.06.005","article-title":"Activation of serotonin 2C receptors in dopamine neurons inhibits binge-like eating in mice","author":"Xu","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1610","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.neuron.2008.09.033","article-title":"5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis","volume":"60","author":"Xu","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1615","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1021\/acschemneuro.5b00017","article-title":"The serotonin 2C receptor agonist lorcaserin attenuates intracranial self-stimulation and blocks the reward-enhancing effects of nicotine","volume":"6","author":"Zeeb","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1620","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuropharm.2015.09.031","article-title":"Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice","volume":"101","author":"Zhang","year":"2016","journal-title":"Neuropharmacology."},{"issue":"13","key":"10.1016\/j.pharmthera.2019.107417_bib1625","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1016\/j.bmcl.2013.04.061","article-title":"Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists","volume":"23","author":"Zhao","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2019.107417_bib1630","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.drudis.2013.08.015","article-title":"Central nervous system biomarkers for antiobesity drug development","volume":"18","author":"Ziauddeen","year":"2013","journal-title":"Drug Discovery Today"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581930169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581930169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:03:18Z","timestamp":1759010598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581930169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":326,"alternative-id":["S016372581930169X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107417","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107417","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107417"}}